RYR2 and catecholaminergic polymorphic ventricular tachycardia: Our findings suggested that most silent or missense mutations may not significantly compromise RYR protein function, because no key mutations were found in known RYR-related diseases, such as catecholaminergic polymorphic ventricular tachycardia (CPVT) (RYR2) or malignant hyperthermia (RYR1)6, 7, indicating that they may not lead to serious phenotypes observed in muscle and heart diseases.